The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

The European Medicines Agency said an eye condition that might cause loss of vision is a very rare side effect of Novo Nordisk's blockbuster drugs Ozempic and Wegovy.

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

The European Medicines Agency’s safety committee said on Friday Novo Nordisk’s popular weight-loss and diabetes drugs Wegovy ...